Informed consent obtained after being advised of the nature of the study

The subject has Type 1 diabetes (as defined by WHO) for at least 24 months

The subject's HbA1c <= 10%

Body Mass Index (BMI) <= 35 kg/m2

The subject is treated with continuous subcutaneous insulin infusion for at least 3 month

Exclusion Criteria:

Subject is actively enrolled in another clinical trial or took part in a study within 30 days

Experienced recurrent severe hypoglycaemic unawareness

Total daily insulin dose >= 1.4 IU/kg

Subject is using a medication that significantly impacts glucose metabolism (oral or topical steroids) except if stable for at least the last three months and expected to remain stable for the study duration

Allergy against insulin Lispro

A history of drug or alcohol dependence

Any other significant concomitant disease such as endocrine, cardiac, neurological, malignant, other pancreatic disease or uncontrolled hypertension as judged by the investigator

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01781533